JP2009502801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502801A5 JP2009502801A5 JP2008522958A JP2008522958A JP2009502801A5 JP 2009502801 A5 JP2009502801 A5 JP 2009502801A5 JP 2008522958 A JP2008522958 A JP 2008522958A JP 2008522958 A JP2008522958 A JP 2008522958A JP 2009502801 A5 JP2009502801 A5 JP 2009502801A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- hydrogen
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 147
- 125000003118 aryl group Chemical group 0.000 claims 135
- 125000001072 heteroaryl group Chemical group 0.000 claims 134
- 229910052739 hydrogen Inorganic materials 0.000 claims 114
- 239000001257 hydrogen Substances 0.000 claims 109
- 150000002431 hydrogen Chemical class 0.000 claims 98
- 125000004404 heteroalkyl group Chemical group 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 61
- 125000002252 acyl group Chemical group 0.000 claims 54
- 238000010276 construction Methods 0.000 claims 41
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 229910052736 halogen Inorganic materials 0.000 claims 34
- 150000002367 halogens Chemical class 0.000 claims 34
- 125000004432 carbon atom Chemical group C* 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 20
- 125000002947 alkylene group Chemical group 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 18
- -1 heteroaliphatic Chemical group 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 16
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 9
- 125000002723 alicyclic group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 102000003989 Aurora kinases Human genes 0.000 claims 3
- 108090000433 Aurora kinases Proteins 0.000 claims 3
- 208000020084 Bone disease Diseases 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 229940124622 immune-modulator drug Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000003900 neurotrophic factor Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000005518 carboxamido group Chemical group 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims 1
- 125000005363 dialkylsulfonamide group Chemical group 0.000 claims 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 0 *[n]1ncc2c1c(I)ncn2 Chemical compound *[n]1ncc2c1c(I)ncn2 0.000 description 23
- QOHLCRQDXAPADP-UHFFFAOYSA-N C[n](cc12)nc1ncnc2I Chemical compound C[n](cc12)nc1ncnc2I QOHLCRQDXAPADP-UHFFFAOYSA-N 0.000 description 1
- OEKDTBVYFDMOMJ-UHFFFAOYSA-N C[n]1nc2c(I)ncnc2c1 Chemical compound C[n]1nc2c(I)ncnc2c1 OEKDTBVYFDMOMJ-UHFFFAOYSA-N 0.000 description 1
- MRGDQLPHEVJGLS-UHFFFAOYSA-N C[n]1nc2c([IH]C)ncnc2c1 Chemical compound C[n]1nc2c([IH]C)ncnc2c1 MRGDQLPHEVJGLS-UHFFFAOYSA-N 0.000 description 1
- MRBIJHKBSSAEBT-UHFFFAOYSA-N Cc1ncnc2n[n](C)cc12 Chemical compound Cc1ncnc2n[n](C)cc12 MRBIJHKBSSAEBT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70169505P | 2005-07-22 | 2005-07-22 | |
| PCT/US2006/028154 WO2007013964A1 (en) | 2005-07-22 | 2006-07-21 | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502801A JP2009502801A (ja) | 2009-01-29 |
| JP2009502801A5 true JP2009502801A5 (enExample) | 2009-09-10 |
Family
ID=37102131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522958A Pending JP2009502801A (ja) | 2005-07-22 | 2006-07-21 | Ａｕｒｏｒａキナーゼインヒビターとして有用なピラゾロピリミジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7932257B2 (enExample) |
| EP (1) | EP1915377A1 (enExample) |
| JP (1) | JP2009502801A (enExample) |
| AU (1) | AU2006272876A1 (enExample) |
| CA (1) | CA2615946A1 (enExample) |
| WO (1) | WO2007013964A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722220C (en) * | 2008-04-30 | 2016-06-07 | National Health Research Institutes | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| CN102232071B (zh) * | 2008-09-26 | 2016-03-23 | 财团法人卫生研究院 | 作为蛋白激酶抑制剂的稠合多环化合物 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| JP2014520874A (ja) | 2011-07-22 | 2014-08-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組成物 |
| US9072301B2 (en) | 2012-02-03 | 2015-07-07 | Basf Se | Fungicidal pyrimidine compounds |
| EA201491667A1 (ru) | 2012-03-13 | 2015-03-31 | Басф Се | Фунгицидные соединения пиримидина |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| PE20150730A1 (es) * | 2012-08-24 | 2015-06-02 | Glaxosmithkline Llc | Compuestos de pirazolopirimidina |
| WO2014081645A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| CA2890201A1 (en) | 2012-11-20 | 2014-05-30 | Glaxosmithkline Llc | Novel compounds |
| AU2013348216B2 (en) | 2012-11-20 | 2016-10-13 | Glaxosmithkline Llc | Novel compounds |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR102469849B1 (ko) | 2013-04-19 | 2022-11-23 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN105722833A (zh) | 2013-09-16 | 2016-06-29 | 巴斯夫欧洲公司 | 杀真菌的嘧啶化合物 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| TWI853814B (zh) | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2980677A (en) * | 1961-04-18 | Certificate of correction | ||
| FR2699176B1 (fr) | 1992-12-11 | 1995-03-03 | Adir | Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant. |
| US6043228A (en) * | 1993-06-08 | 2000-03-28 | Cancer Research Campaign Technology Limited | O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells |
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5929046A (en) | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
| WO1997023480A1 (en) | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| DE69736711T2 (de) | 1996-08-28 | 2007-09-20 | Pfizer Inc. | Substituierte 6,5-heterobicyclische-derivate |
| US20010007867A1 (en) * | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| US5723608A (en) * | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| AU3514200A (en) | 1999-03-10 | 2000-09-28 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| JP2002539124A (ja) | 1999-03-10 | 2002-11-19 | メルク エンド カムパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物 |
| IL148903A0 (en) * | 1999-09-30 | 2002-09-12 | Neurogen Corp | Certain alkylene diamine-substituted heterocycles |
| EP1244668B1 (en) * | 2000-01-07 | 2006-04-05 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
| JP4498741B2 (ja) * | 2001-12-24 | 2010-07-07 | アストラゼネカ アクチボラグ | オーロラキナーゼ阻害剤としての置換キナゾリン誘導体 |
| DE60237425D1 (de) | 2002-03-28 | 2010-10-07 | Univerzita Palackeho V Olomouc | PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung |
| WO2004009602A1 (en) * | 2002-07-23 | 2004-01-29 | Smithkline Beecham Corporation | Pyrazolopyrimidines as kinase inhibitors |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| EP1620437B1 (en) | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
| US7221979B2 (en) | 2003-04-30 | 2007-05-22 | Medtronic, Inc. | Methods and apparatus for the regulation of hormone release |
| DE60333546D1 (de) * | 2003-05-06 | 2010-09-09 | Univ Palackeho | PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung |
| AR045697A1 (es) * | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| EP2145888A1 (en) * | 2003-09-18 | 2010-01-20 | Conforma Therapeutics Corporation | Deazapurine derivatives as HSP90-Inhibitors |
| JP4800216B2 (ja) | 2003-10-24 | 2011-10-26 | エグゼリクシス， インコーポレイテッド | ｐ７０Ｓ６キナーゼモジュレーターおよび使用方法 |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| MXPA06013996A (es) * | 2004-06-02 | 2007-02-08 | Takeda Pharmaceutical | Compuesto heterociclico fusionado. |
-
2006
- 2006-07-21 JP JP2008522958A patent/JP2009502801A/ja active Pending
- 2006-07-21 CA CA002615946A patent/CA2615946A1/en not_active Abandoned
- 2006-07-21 AU AU2006272876A patent/AU2006272876A1/en not_active Abandoned
- 2006-07-21 WO PCT/US2006/028154 patent/WO2007013964A1/en not_active Ceased
- 2006-07-21 EP EP06800152A patent/EP1915377A1/en not_active Withdrawn
- 2006-07-21 US US11/490,983 patent/US7932257B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502801A5 (enExample) | ||
| JP2008506714A5 (enExample) | ||
| EP3490987B1 (en) | Novel therapeutic agents for the treatment of hbv infection | |
| ES2566797T3 (es) | Compuestos de polímero de polialquileno y usos de éstos | |
| TW202039005A (zh) | 新穎之抑制細胞生長的整合素配體綴合物 | |
| TWI740910B (zh) | 非環抗病毒劑 | |
| JP2008523099A5 (enExample) | ||
| KR20170020923A (ko) | 표적화된 콘주게이트 및 입자 및 그것의 제형 | |
| CA2463284A1 (en) | Pyrimidine compounds and pharmaceutical compositions containing the compounds | |
| CN111971284A (zh) | 核苷和/或nadph氧化酶(nox)抑制剂作为髓样特异性抗病毒剂的联合模式 | |
| JP2012526838A5 (enExample) | ||
| JP2021178820A (ja) | 脳癌の治療 | |
| JP2013542996A5 (enExample) | ||
| PT1615640E (pt) | Combinações antineoplásticas | |
| AU5755499A (en) | Fc receptor modulators and uses thereof | |
| KR20070102741A (ko) | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 | |
| MX2008014520A (es) | Preparacion de conjugados polimericos de compuestos terapeuticos, agricolas, y de aditivos para alimentos. | |
| CA3012951A1 (en) | Copanlisib biomarkers | |
| TW202033515A (zh) | 用於治療c型肝炎病毒之高活性藥物組合 | |
| JP2018529777A (ja) | Ｈｃｖの治療に対する併用療法レジメン | |
| JP2006508965A5 (enExample) | ||
| KR20170120568A (ko) | 생리활성물질결합 블록 공중합체 | |
| JP2025027020A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| WO2024109964A1 (zh) | 一种口服载药胶束组合物及其制备方法 | |
| CN111093717B (zh) | 靶向性纳米颗粒 |